Adaptimmune Therapeutics Plc ADR (ADAP)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

60 JUBILEE AVENUE ABINGDON, OXFORDSHIRE, UNITED KINGDOM OX14 4RX

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. The Company develops novel cancer immunotherapy products based on T-cell receptor platform that helps to identify cancer targets. Adaptimmune Therapeutics serves customers worldwide.

Data as of 2020-07-04
Market Cap1.505 Billion Shares Outstanding153.684 Million Avg 30-day Volume5.887 Million
P/E Ratio Dividend Yield EPS-1.32
Price/Sales871.708 Price cash flow ratio30.4 Price free cash flow ratio-57.8
Book Value1.21 Price to Tangible Book8.36 Alpha0.04
Short Interest Ratio % Short Interest to Float R-squared0.049154
BETA2.42654 52-week High/Low13.4 / 0.709 Stddev0.466082
View SEC Filings from ADAP instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 49 15 (0.98%)
Aggregate 13F shares on 03/31/2020: 93.846 Million 61.488 Million
Aggregate 13F shares on 12/31/2019: 64.877 Million 34.02 Million
Percent change: 44.65% 80.74%
Funds creating new positions: 14 5
Funds Adding to an existing position: 15 5
Funds closing out their position: 9 2
Funds reducing their position: 10 2
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ADAP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADAP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

45.9 Thousand total shares from 2 transactions

Open Market Sells (S)

500 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FLORENCE ANTHONY A. JR.

  • 10% Owner
0 2020-07-09 1

BEHBAHANI ALI

  • Director
0 2020-07-09 2

BASKETT FOREST

  • 10% Owner
0 2020-07-09 1

SONSINI PETER W.

  • 10% Owner
0 2020-07-09 1

SANDELL SCOTT D

  • 10% Owner
0 2020-07-09 1

ZAKS TAL ZVI CHIEF MEDICAL OFFICER

  • Officer
0 2020-07-07 1

NOBLE JAMES

  • Director
0 2020-07-01 4

ALLEVA LAWRENCE M

  • Director
0 2020-07-01 2

SIGAL CHARLES ELLIOTT

  • Director
0 2020-07-01 1

MOTT DAVID M

  • Director
0 2020-07-01 2

DUNCAN BARBARA GAYLE

  • Director
0 2020-07-01 1

FUREY JOHN

  • Director
0 2020-07-01 1

WOOD GAVIN CHIEF FINANCIAL OFFICER

  • Officer
33,000 2020-06-29 3

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

  • Director
  • 10% Owner
12,714,404 2020-06-19 0

THOMPSON PETER A.

  • Director
  • 10% Owner
0 2020-06-17 0

KERINS PATRICK J

  • 10% Owner
8,097,725 2020-06-10 0

BERTRAND WILLIAM C JR

  • Director
59,658 2020-06-09 3

BARRIS PETER J

  • Director
6,420 2020-05-27 0

AMADO RAFAEL EVP OF R&D AND CMO

135,962 2020-03-18 1

TAYTON-MARTIN HELEN KATRINA CHIEF BUSINESS OFFICER

  • Officer
0 2020-01-16 2

RAWCLIFFE ADRIAN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-01-16 4

LUNGER JOHN CHIEF PATIENT SUPPLY OFFICER

  • Officer
0 2020-01-16 5

NORRY ELLIOT CHIEF MEDICAL OFFICER

  • Officer
0 2020-01-16 3

GARONE MICHAEL INTERIM CFO

  • Officer
0 2019-10-01 1

KERR GILES FRANCIS BERTRAM

  • Director
0 2019-07-02 0

BARRETT M JAMES

  • Director
0 2019-05-30 0

BINDER-SCHOLL GWENDOLYN KNOWLTON CHIEF TECHNOLOGY OFFICER

  • Officer
2,487 2019-01-14 0

VISWANATHAN RAVI

  • 10% Owner
5,000,000 2018-10-17 0

NEW ENTERPRISE ASSOCIATES 14, L.P.

NEA PARTNERS 14, L.P.

NEA 14 GP, LTD

  • 10% Owner
82,978,668 2018-09-07 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

ISALY SAMUEL D

  • Director
941,000 2017-12-08 0

KOLLURI KRISHNA KITTU

  • 10% Owner
5,215,128 2016-12-19 0

WELLER HARRY R

  • 10% Owner
3,490,073 2016-10-31 0

KNOWLES JONATHAN KENNETH CHARLES

  • Director
0 2016-08-11 0

LAING IAN MICHAEL

  • Director
0 2016-08-11 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

BEHBAHANI ALI - Director

2020-07-01 A 184,258 a 184,258 0.00 direct

MOTT DAVID M - Director

2020-07-01 A 226,753 a 226,753 0.00 direct

FUREY JOHN - Director

2020-07-01 A 196,186 a 196,186 0.00 direct

ALLEVA LAWRENCE M - Director

2020-07-01 A 197,678 a 197,678 0.00 direct

NOBLE JAMES - Director

2020-07-01 A 179,785 a 179,785 0.00 direct

SIGAL CHARLES ELLIOTT - Director

2020-07-01 A 184,258 a 184,258 0.00 direct

DUNCAN BARBARA GAYLE - Director

2020-07-01 A 144,000 a 144,000 0.00 direct

ZAKS TAL ZVI - Director

2020-07-01 A 144,000 a 144,000 0.00 direct

WOOD GAVIN - Officer CHIEF FINANCIAL OFFICER

2020-06-29 P 33,000 $1.62 a 33,000 33,000.00 direct

ALLEVA LAWRENCE M - Director held by trust

2020-06-09 P 12,900 $1.89 a 12,900 130,764.00 indirect

NOBLE JAMES - Director

2020-05-29 S 500,000 $9.33 d 0 0.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments